Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.2B
46M shares
52-week range
$15.93 – $41.73
37% from low
Sector
SPECIAL INDUSTRY MACHINERY, NEC
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $631.6M | $780.8M | $388.5M | $513.7M | $555.5M | $665.1M | $573.4M | $593.8M |
| Cost of revenue | $404.8M | $488.8M | $243.7M | $299.2M | $324.9M | $431.8M | $318.8M | $323.5M |
| Gross profit | $226.7M | $292.0M | $144.9M | $214.5M | $230.6M | $233.3M | $254.6M | $270.3M |
| Gross margin | 35.9% | 37.4% | 37.3% | 41.8% | 41.5% | 35.1% | 44.4% | 45.5% |
| R&D | $46.9M | $56.4M | $16.1M | $22.4M | $27.5M | $34.0M | $31.5M | $30.4M |
| Operating income | $34.4M | $55.1M | −$27.5M | $3.6M | −$24.0M | −$82.2M | −$30.0M | −$11.3M |
| EBITDA | $66.7M | $86.1M | $28.1M | $9.9M | $48.4M | $55.2M | $71.6M | $54.1M |
| Net income | $116.6M | $28.8M | $64.9M | $110.7M | −$429.0M | −$14.3M | −$164.9M | −$55.8M |
| Net margin | 18.5% | 3.7% | 16.7% | 21.6% | -77.2% | -2.1% | -28.8% | -9.4% |
| EPS (diluted) | 1.64 | 0.14 | 0.88 | -0.39 | -0.15 | -0.22 | -3.09 | -1.22 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $600M | $0.45 | $0.44–$0.45 | 3 |
| 2027 | $630M | $0.61 | $0.60–$0.62 | 2 |
| 2028 | $675M | $0.85 | $0.80–$0.89 | 2 |
| 2029 | $684M | $1.30 | $1.27–$1.31 | 1 |
Forward consensus · source: Financial Modeling Prep
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
www.azenta.comNo one on the platform currently holds AZTA.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 26,833 | $567.0K |
| Renaissance Technologiesas of 2025-03-31 | 16,344 | $566.2K |
No one on the platform has traded AZTA yet.
| $1.5B |
| — |
| NEOGNeogen Corporation | $9.58 | +0.74% | $2.1B | — |
| NVCRNovocure Ltd | $15.43 | +2.52% | $1.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 2.3× sales vs its 5.0× historical median P/S.
Fair value ≈ $55.00 · price $25.51 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$AZTA Share Price: $22.81 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $4.33 – $5.35 Target Zone: $8.06 – $9.85 Potential Upside: 75% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$AZTA biggest competitor got marked as a Chinese military company! They’re gonna gain marketshare 👀 in for a recovery to 30-40 by eoy
View on StockTwits ↗$AZTA 🚨 18 JUN 26 $25 CALL $0.70 HUGE GAP ABOVE + SECTOR SENTIMENT + HIGH CONFIDENCE
View on StockTwits ↗$AZTA 18 JUN 26 $25 CALL $0.70 HUGE GAP ABOVE + SECTOR SENTIMENT + HIGH CONFIDENCE
View on StockTwits ↗$AZTA is attempting to build a floor and break its descending trendline after a catastrophic earnings gap-down on the back of slashed guidance and a massive impairment charge. 🌊 This is a high-risk structural reset for the life sciences giant. With the massive Q2 margin collapse fully priced in and the stock taking a historic haircut, bottom-fishers are actively positioning for a mean-reversion squeeze. However, management's lowered full-year outlook keeps the fundamental overhang incredibly heavy, leaving very little room for error on the immediate roadmap. 🎯 🐂 Bulls want to hold the 17.60 baseline to force a clean daily close over 20.39 targeting the heavy 22.67 supply shelf 🐻 Bears need to crack 17.60 to kill the dead-cat bounce and trigger a new wave of capitulation 📊 Lean NEUTRAL. #azta #trading #hovdid
View on StockTwits ↗$AZTA putting in a flat capitulation base right at the $18.50 demand floor after a heavy fiscal Q2 guidance reset 🌋 Life sciences play holds an absolute fortress balance sheet: $580M in pure cash and ZERO debt. Current market cap heavily discounts assets. ... 🐻 Bears need a break under $18.50 to test the deeper $15.00 cash floor. 📊 Lean neutral-to-BULLISH. Severe execution shortfalls are out, but the massive cash cushion de-risks the downside. Watch for the turn. #AZTA #hovdid
View on StockTwits ↗$AZTA down from $41 to $15.94 and now bouncing 5.15% off capitulation volume. Azenta life sciences automation — sample management, genomic services, biobanking. Volume exhaustion at the lows confirmed the bottom. ITM $17.5 call sweep just hit with spot at $17.86. RSI launching from near 20. Someone decided the floor is in. 🐂 $18.57 holds and $19.60 then $22 then $24.24 happen in sequence. Capitulation volume + ITM call sweep + RSI recovery = three reasons to pay attention. 🐻 $17.60 loses and the bounce was just relief. $16.94 then $15.94 retest. Life sciences spending still under pressure. ⚠️ ITM call sweep same day as the capitulation volume bounce. That's not random timing. Bottom volume printed. Sweep confirmed. Recovery has a case. #AZTA #Azenta #LifeSciences #OptionsFlow #TechnicalAnalysis #hovdid
View on StockTwits ↗$AZTA — Azenta. Life sciences automation, biobanking, genomics services. Has spent 4 years in one of the most brutal downtrends on any chart — $90 to $7.94. Multi-decade low hit. Gap from 2016 finally filled. Volume exhaustion on the capitulation wick. And today it's up 8.68%. 🐂 Gap fill + volume exhaustion at decade lows = capitulation bottom thesis. $19 reclaim → $25–29. Activist or strategic catalyst = violent squeeze. 🐻 Every rally in this downtrend has been sold. Pink trendline from 2021 is still miles above. Life sciences spending still under pressure. ⚠️ $7.94 decade low + gap fill + 8.68% bounce today. Either the bottom is in or this is a dead cat. Volume on the flush suggests real capitulation. #AZTA #Azenta #LifeSciences #Biotech #TechnicalAnalysis #hovdid
View on StockTwits ↗$AZTA the market is rewarding anyone who stayed patient.
View on StockTwits ↗$AZTA Insider purchase: https://www.sec.gov/Archives/edgar/data/933974/000119312526230764/xslF345X06/ownership.xml
View on StockTwits ↗$AZTA Current Stock Price: $19.22 Contracts to trade: $20.0 AZTA May 15 2026 Call Entry: $1.01 Exit: $1.39 ROI: 38% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$AZTA loading up 12 shares after the crash following bad earnings.
View on StockTwits ↗$AZTA reported -0.04 EPS and 144.80 revenue for Q2. http://www.estimize.com/intro/azta?chart=historical&metric_name=eps&utm_content=AZTA&ut
View on StockTwits ↗$AZTA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$3.49 down -772.50% YoY • Reported revenue of $144.79M up 0.96% YoY • Azenta expects FY'26 total reported revenue from continuing operations to be $603M-$621M. Organic revenue is now projected down 2% to up 1%, a reduction from prior guidance, and Adjusted EBITDA margin is expected down 125 bps to flat.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.